Showing 2201-2210 of 9396 results for "".
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared w
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- FDA Seeks More Information on Pliaglishttps://practicaldermatology.com/news/20120419-fda_seeks_more_information_on_pliaglis/2459818/FDA's Complete Response Letter to Galderma Laboratories LP outlines additional information the FDA requires before it will approve the sNDA for Pliaglis, developer Nuvo Research, Inc. reports. The response is to the supplemental New Drug App
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459833/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Atlantic Dermatological Conference to be Held Next Monthhttps://practicaldermatology.com/news/20120320-atlantic_dermatological_conference_to_be_held_next__month/2459834/The 89th Atlantic Dermatological Conference hosted by the Dermatologic Society of Greater New York will be held April 27-29 at the Grand Hyatt Hotel, New York City. Register Online at DermSociety.org.
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- VALOR Data Show Sustained Skin Improvement With Brepocitinibhttps://practicaldermatology.com/news/valor-data-show-sustained-skin-improvement-with-brepocitinib/2488826/Once-daily oral brepocitinib 30 mg demonstrated rapid and sustained improvements in cutaneous disease activity, pruritus, and skin-related quality of life among adults with dermatomyositis, according to a prespecified secondary analysis of the phase 3 VALOR trial published in JAMA Dermatology
- Analysis Identifies Distinct Keratinocyte and Fibroblast Niches in Severe HShttps://practicaldermatology.com/news/study-examines-pathogenic-keratinocyte-states-and-fibroblast-niches-in-severe-hs/2488815/Researchers identified a pathogenic keratinocyte state and spatially distinct fibroblast populations in severe hidradenitis suppurativa (HS), providing new insights into epithelial–stromal and immune cell interactions that may contribute to disease persistence. The study authors, publishin
- National Rosacea Society Awards $25,000 for Research on Rosacea Pathogenesis and Treatmenthttps://practicaldermatology.com/news/national-rosacea-society-awards-25000-for-research-on-rosacea-pathogenesis-and-treatment/2488784/The National Rosacea Society (NRS) has awarded two research grants totaling $25,000 to support investigations into the underlying mechanisms of rosacea, including vascular inflammation, immune system interactions, and the potential association between Helicobacter pylori infection and di
- Fall Clinical Talk Highlights KIT Inhibition's Promise for Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/fall-clinical-talk-highlights-kit-inhibitions-promise-for-chronic-spontaneous-urticaria/2488733/Emerging evidence supports KIT inhibition as a novel therapeutic approach, Naiem Issa, MD, PhD, FAAD, said in a talk at the 2026 Fall Clinical Dermatology Conference. Targeting the KIT signaling pathway may offer a new treatment strategy for patients with chronic spontaneous urticaria (CSU